|
GTF2A2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.22044604925031E-16 |
| Normal-vs-Stage2 |
2.49020026821256E-10 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
6.923200E-01 |
| Stage1-vs-Stage3 |
9.473600E-02 |
| Stage1-vs-Stage4 |
6.10999999999251E-05 |
| Stage2-vs-Stage3 |
4.488000E-01 |
| Stage2-vs-Stage4 |
4.655200E-03 |
| Stage3-vs-Stage4 |
7.038500E-03 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.72139999979437E-07 |
| Normal-vs-Asian |
2.7902014032577E-11 |
| Caucasian-vs-AfricanAmerican |
7.688800E-01 |
| Caucasian-vs-Asian |
5.564800E-01 |
| AfricanAmerican-vs-Asian |
9.129600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
1.775810E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.626032641866E-12 |
| Normal-vs-Age(81-100Yrs) |
1.241330E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.376800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.550240E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.073600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.531600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.698400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.070800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.311900E-02 |
| Classical-VS-Follicular |
8.968600E-01 |
| Classical-VS-Other |
3.342000E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
9.342100E-02 |
| Tall-VS-Other |
9.871200E-01 |
| Tall-VS-Normal |
2.23088214568179E-12 |
| Follicular-VS-Other |
4.520000E-01 |
| Follicular-VS-Normal |
1.0327960708878E-11 |
| Other-VS-Normal |
3.57360000000639E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.11732886568461E-14 |
| Normal-vs-N1 |
1.4432899320127E-15 |
| N0-vs-N1 |
2.244300E-02 |
|
|
